ZP
STOK icon

Zimmer Partners’s Stoke Therapeutics STOK Stock Holding History

Zimmer Partners’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-25,000
Closed -$708K – 103
2019
Q4 		$708K Hold
25,000
– – 0.01% 76
2019
Q3 		$537K Hold
25,000
– – 0.01% 98
2019
Q2 		$729K Buy
+25,000
New +$671K 0.01% 97

Other funds holding STOK

ALSV
ATP Life Science Ventures New York $898M AUM 84.86% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Zimmer Partners's STOK Position: Q1 2020 in Review

Zimmer Partners sold out of Stoke Therapeutics (STOK) in Q1 2020, closing a stake of 25,000 shares — an estimated $708K sold.

Zimmer Partners first reported a position in STOK in Q2 2019 and held it in 3 quarters. The position peaked at $729K in Q2 2019. 67 funds tracked by Wall St. Rank hold STOK as of Q1 2020.

  • Zimmer Partners reported no remaining Stoke Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Zimmer Partners sold 25,000 Stoke Therapeutics shares in Q1 2020, an estimated $708K.
  • Zimmer Partners first reported a position in Stoke Therapeutics in Q2 2019 and held it in 3 quarters.
  • Zimmer Partners's Stoke Therapeutics position peaked at $729K in Q2 2019.
  • 67 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2020.

Based on Zimmer Partners's 13F filing for Q1 2020, filed 15 May 2020.